New uses help Abilify to another strong US quarter
This article was originally published in Scrip
Executive Summary
US net sales of Abilify (aripiprazole) rose by 6% to $897 million in the first quarter ended 31 March, in line with the atypical antipsychotic's growth over the whole of last year, new unaudited figures from originator Otsuka show.